🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

223+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 223 recruiting trials for “acute-promyelocytic-leukemia

Phase 2RecruitingNCT06124157

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

👨‍⚕️ Thai Hoa Tran, Children's Oncology Group📍 139 sites📅 Started May 2025View details ↗
Phase 1, PHASE2RecruitingNCT06533579

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

👨‍⚕️ Vironexis Clinical Trials, Vironexis Biotherapeutics Inc.📍 9 sites📅 Started May 2025View details ↗
EARLY_Phase 1RecruitingNCT06980155

XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia

🏥 Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started May 2025View details ↗
NARecruitingNCT06940960

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia

👨‍⚕️ Jinqi Huang, PhD, Guangzhou First People's Hospital📍 1 site📅 Started May 2025View details ↗
Phase 2RecruitingNCT06847269

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

👨‍⚕️ Aimee Talleur, MD, St. Jude Children's Research Hospital📍 1 site📅 Started May 2025View details ↗
Phase 2RecruitingNCT07256210

Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation

🏥 Federal Research Institute of Pediatric Hematology, Oncology and Immunology📍 1 site📅 Started May 2025View details ↗
Phase 1RecruitingNCT06934382

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

👨‍⚕️ Caroline Diorio, MD, Children's Hospital of Philadelphia📍 1 site📅 Started Apr 2025View details ↗
Phase 1RecruitingNCT06047886

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

🏥 University of Alabama at Birmingham📍 1 site📅 Started Apr 2025View details ↗
Phase 1RecruitingNCT07347171

A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies

👨‍⚕️ Jianxiang Wang, MS, The Haematology Hospital of the Chinese Academy of Medical Sciences📍 3 sites📅 Started Apr 2025View details ↗
Phase 1RecruitingNCT06834282

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

🏥 CERo Therapeutics Holdings, Inc.📍 4 sites📅 Started Apr 2025View details ↗
Phase 2RecruitingNCT07012447

Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations

👨‍⚕️ Yue-jun Liu, The First Affiliated Hospital of Soochow University📍 1 site📅 Started Apr 2025View details ↗
Phase 1RecruitingNCT06879340

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

👨‍⚕️ Joseph McGuirk, D.O., University of Kansas Medical Center📍 1 site📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06559345

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL

👨‍⚕️ Xiangbo Wan, PhD., The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06304103

A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

👨‍⚕️ Yusha Zhu, MD, PhD, Kind Pharmaceuticals LLC📍 1 site📅 Started Mar 2025View details ↗
Phase 1RecruitingNCT06950034

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

👨‍⚕️ Chief Medical Officer, MD, MSc, MBA, Solu Therapeutics📍 7 sites📅 Started Mar 2025View details ↗
Phase 1RecruitingNCT03816319

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

👨‍⚕️ Guillaume Richard-Carpentier, University Health Network Princess Margaret Cancer Center LAO📍 5 sites📅 Started Mar 2025View details ↗
Phase 2, PHASE3RecruitingNCT06855810

Newly-diagnosed Pediatric T-cell ALL Protocol

👨‍⚕️ Xiaofan Zhu, MD, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC📍 27 sites📅 Started Mar 2025View details ↗
NARecruitingNCT06773871

Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions

🏥 Rigshospitalet, Denmark📍 2 sites📅 Started Mar 2025View details ↗
Phase 2, PHASE3RecruitingNCT06882057

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

👨‍⚕️ Xiaofan Zhu, MD, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC📍 27 sites📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06557161

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL

🏥 The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Mar 2025View details ↗
← PreviousPage 3 of 12Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →